| MeSH term | MeSH ID | Detail |
|---|---|---|
| Syphilis | D013587 | 6 associated lipids |
| Hearing Disorders | D006311 | 10 associated lipids |
| Encephalomyelitis, Autoimmune, Experimental | D004681 | 26 associated lipids |
| Infant, Newborn, Diseases | D007232 | 9 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Uterine Cervicitis | D002575 | 3 associated lipids |
| Neutropenia | D009503 | 15 associated lipids |
| Lung Diseases, Obstructive | D008173 | 10 associated lipids |
| Urticaria | D014581 | 13 associated lipids |
| Escherichia coli Infections | D004927 | 17 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Bingen E et al. | Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections. | 2003 | Antimicrob. Agents Chemother. | pmid:12821495 |
| Matlow A et al. | Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. | 1998 | Antimicrob. Agents Chemother. | pmid:9593171 |
| Pettus K et al. | In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae. | 2015 | Antimicrob. Agents Chemother. | pmid:25624328 |
| Retsema J et al. | Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. | 1987 | Antimicrob. Agents Chemother. | pmid:2449865 |
| Nash KA and Inderlied CB | Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. | 1995 | Antimicrob. Agents Chemother. | pmid:8592991 |
| Bohte R et al. | Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. | 1995 | Antimicrob. Agents Chemother. | pmid:8593024 |
| Rodvold KA et al. | Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. | 2003 | Antimicrob. Agents Chemother. | pmid:12878504 |
| Dunne MW et al. | Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis. | 2003 | Antimicrob. Agents Chemother. | pmid:12878537 |
| Girard AE et al. | Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. | 1987 | Antimicrob. Agents Chemother. | pmid:2830841 |
| Chang HR and Pechère JC | In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii. | 1988 | Antimicrob. Agents Chemother. | pmid:2837140 |
| Hammerschlag MR et al. | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. | 1992 | Antimicrob. Agents Chemother. | pmid:1324650 |
| Ednie LM et al. | Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. | 1996 | Antimicrob. Agents Chemother. | pmid:8843313 |
| Mulet X et al. | Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. | 2009 | Antimicrob. Agents Chemother. | pmid:19188376 |
| Cynamon MH and Klemens SP | Activity of azithromycin against Mycobacterium avium infection in beige mice. | 1992 | Antimicrob. Agents Chemother. | pmid:1329622 |
| Seyama S et al. | Amino Acid Substitution in the Major Multidrug Efflux Transporter Protein AcrB Contributes to Low Susceptibility to Azithromycin in Haemophilus influenzae. | 2017 | Antimicrob. Agents Chemother. | pmid:28848006 |
| Jacobs MR et al. | Study design questions in treatment of children with acute otitis media. | 2004 | Antimicrob. Agents Chemother. | pmid:15241848 |
| Tateda K et al. | Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891128 |
| Kemp MW et al. | Maternal intravenous administration of azithromycin results in significant fetal uptake in a sheep model of second trimester pregnancy. | 2014 | Antimicrob. Agents Chemother. | pmid:25155606 |
| Hunt Gerardo S et al. | Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8891154 |
| Zheng S et al. | Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. | 2014 | Antimicrob. Agents Chemother. | pmid:25155592 |
| Neoh CF et al. | Rapid and sensitive liquid chromatography/mass spectrometry assay for caspofungin in human aqueous humor. | 2010 | Antimicrob. Agents Chemother. | pmid:20660672 |
| Engel JN | Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. | 1992 | Antimicrob. Agents Chemother. | pmid:1280057 |
| Saini H et al. | Azithromycin-Ciprofloxacin-Impregnated Urinary Catheters Avert Bacterial Colonization, Biofilm Formation, and Inflammation in a Murine Model of Foreign-Body-Associated Urinary Tract Infections Caused by Pseudomonas aeruginosa. | 2017 | Antimicrob. Agents Chemother. | pmid:28031194 |
| Girgis NI et al. | Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. | 1999 | Antimicrob. Agents Chemother. | pmid:10348767 |
| Binet R and Maurelli AT | Frequency of development and associated physiological cost of azithromycin resistance in Chlamydia psittaci 6BC and C. trachomatis L2. | 2007 | Antimicrob. Agents Chemother. | pmid:17908942 |
| Wolf K and Malinverni R | Effect of azithromycin plus rifampin versus that of azithromycin alone on the eradication of Chlamydia pneumoniae from lung tissue in experimental pneumonitis. | 1999 | Antimicrob. Agents Chemother. | pmid:10348778 |
| Ngo LY et al. | Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team. | 1999 | Antimicrob. Agents Chemother. | pmid:10348786 |
| Walsh M et al. | In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis. | 1987 | Antimicrob. Agents Chemother. | pmid:3038010 |
| Starner TD et al. | Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and Diminish established biofilms. | 2008 | Antimicrob. Agents Chemother. | pmid:17954687 |
| Zasowski E et al. | Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin. | 2014 | Antimicrob. Agents Chemother. | pmid:24752270 |
| Rouse MS et al. | Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. | 1997 | Antimicrob. Agents Chemother. | pmid:9257739 |
| Wong MH et al. | Emergence of clinical Salmonella enterica serovar Typhimurium isolates with concurrent resistance to ciprofloxacin, ceftriaxone, and azithromycin. | 2014 | Antimicrob. Agents Chemother. | pmid:24752251 |
| Marvig RL et al. | Mutations in 23S rRNA confer resistance against azithromycin in Pseudomonas aeruginosa. | 2012 | Antimicrob. Agents Chemother. | pmid:22644032 |
| Clark CL et al. | Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. | 2007 | Antimicrob. Agents Chemother. | pmid:17876003 |
| Köhler T et al. | Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. | 2007 | Antimicrob. Agents Chemother. | pmid:17876004 |
| Mandell GL and Coleman EJ | Activities of antimicrobial agents against intracellular pneumococci. | 2000 | Antimicrob. Agents Chemother. | pmid:10952618 |
| Freeman CD et al. | Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. | 1994 | Antimicrob. Agents Chemother. | pmid:7840585 |
| Agacfidan A et al. | In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. | 1993 | Antimicrob. Agents Chemother. | pmid:8239579 |
| Tomazic J et al. | In vivo administration of azithromycin affects lymphocyte activity in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:8239585 |
| Cantin L and Chamberland S | In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. | 1993 | Antimicrob. Agents Chemother. | pmid:8239619 |
| Allen GP and Harris KA | Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin. | 2017 | Antimicrob. Agents Chemother. | pmid:28483960 |
| Barry AL et al. | In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. | 1988 | Antimicrob. Agents Chemother. | pmid:2840016 |
| Critchley IA et al. | National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study. | 2007 | Antimicrob. Agents Chemother. | pmid:17908940 |
| Jacks SS et al. | In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. | 2003 | Antimicrob. Agents Chemother. | pmid:12709351 |
| Roord JJ et al. | Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. | 1996 | Antimicrob. Agents Chemother. | pmid:9124837 |
| Gödeke J et al. | Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa. | 2013 | Antimicrob. Agents Chemother. | pmid:23318806 |
| Nagaoka K et al. | Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. | 2013 | Antimicrob. Agents Chemother. | pmid:23380724 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |
| Lee N et al. | Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. | 2017 | Antiviral Res. | pmid:28535933 |
| Allen G | Evidence appraisal of Tita ATN, Szychowski JM, Boggess K, et al. Adjunctive azithromycin prophylaxis for cesarean delivery.: N Engl J Med. 2016;375:1231-1241. | 2017 | AORN J | pmid:28034388 |